
Journal Club: Efficacy & Safety of Nanoencapsulated Sirolimus Plus Pegadricase
In this RhAPP journal club video module, Danielle Gatti-Palumbo, PharmD reviews the efficacy and safety of nanoencapsulated sirolimus plus pegadricase (NASP) in patients with uncontrolled gout, based on findings from the randomized, placebo-controlled Phase 3 DISSOLVE I and II trials. She explains how nanoencapsulated sirolimus is designed to reduce anti-drug antibody formation and support sustained serum urate lowering with pegadricase, addressing a key challenge in uricase-based gout treatment. This episode examines the study design, every-four-week dosing regimen, serum urate response, tophus resolution, tender joint counts, and health-related quality of life. Danielle discusses improved serum urate control compared with placebo, along with key safety considerations, including gout flares, stomatitis, infusion-related reactions, and anaphylaxis. She also evaluates the study’s strengths and limitations, including the 24-week analysis period and the absence of a direct comparison with pegloticase plus methotrexate. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, pharmacists, and clinicians caring for patients with uncontrolled or tophaceous gout, this journal club provides a practical overview of an investigational urate-lowering therapy, its potential benefits, and important considerations when interpreting the clinical trial results. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.